RxDoctor Payments Data

Peter Trottier, MD

Family Medicine · Marietta, GANPI 1235112947

Payments from drug & device makers

$8,177in general payments, 2019–2025

Across 478 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$823
  • AbbVie$815
  • Pfizer$628
  • AstraZeneca$626
  • GSK$372
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,171100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,177 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$157,617
Medicare patients
555
Services billed
4,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$105,143
RybelsusSemaglutide51$76,924
JardianceEmpagliflozin64$75,992
FarxigaDapagliflozin Propanediol42$49,297
JanuviaSitagliptin Phosphate34$44,366
EliquisApixaban27$29,695
MounjaroTirzepatide28$29,267
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,705
TrulicityDulaglutide20$18,677
Janumet XrSitagliptin Phos/Metformin Hcl13$18,279
MyrbetriqMirabegron20$15,307
LinzessLinaclotide20$14,797
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$12,563
SynthroidLevothyroxine Sodium90$8,169
Tresiba Flextouch U-100Insulin Degludec11$7,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,201$182,067129 claims
Boehringer IngelheimJardiance$145$75,99264 claims
MerckJanuvia, Janumet Xr$89$62,64547 claims
AstraZenecaFarxiga$626$49,29742 claims
Lilly USA, LLCMounjaro, Trulicity$281$47,94348 claims
PfizerEliquis, Premarin$628$33,97039 claims
AbbVieLinzess, Synthroid$815$22,966110 claims
GSKTrelegy Ellipta$372$20,70523 claims
Astellas Pharma US IncMyrbetriq$249$15,30720 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$4,140404 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →